Grand Pharmaceutical Proposes Replacing HLB With Deloitte as Auditor

PUBT · 2d ago
Grand Pharmaceutical Proposes Replacing HLB With Deloitte as Auditor
  • Grand Pharmaceutical Group proposes replacing HLB Hodgson Impey Cheng with Deloitte Touche Tohmatsu for the year ending December 31, 2026.
  • The change requires shareholder approval on November 25, 2026, reflecting a push for broader international audit coverage to support overseas expansion.
  • Deloitte's proposed audit fee is approximately HK$ 4.38 million, compared with HK$ 4.35 million paid to HLB for 2025.
  • No disagreements or unresolved audit matters were identified between HLB and the company.
  • The switch is not expected to materially affect the annual audit or results release; Deloitte targets audit completion in March 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261105-12402092), on November 05, 2026, and is solely responsible for the information contained therein.